JP2022552834A5 - - Google Patents

Info

Publication number
JP2022552834A5
JP2022552834A5 JP2022521147A JP2022521147A JP2022552834A5 JP 2022552834 A5 JP2022552834 A5 JP 2022552834A5 JP 2022521147 A JP2022521147 A JP 2022521147A JP 2022521147 A JP2022521147 A JP 2022521147A JP 2022552834 A5 JP2022552834 A5 JP 2022552834A5
Authority
JP
Japan
Prior art keywords
group
unsubstituted
substituted
formula
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022521147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552834A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054896 external-priority patent/WO2021072140A1/en
Publication of JP2022552834A publication Critical patent/JP2022552834A/ja
Publication of JP2022552834A5 publication Critical patent/JP2022552834A5/ja
Pending legal-status Critical Current

Links

JP2022521147A 2019-10-10 2020-10-09 ミエロペルオキシダーゼ阻害剤のプロドラッグ Pending JP2022552834A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913417P 2019-10-10 2019-10-10
US62/913,417 2019-10-10
PCT/US2020/054896 WO2021072140A1 (en) 2019-10-10 2020-10-09 Prodrugs of myeloperoxidase inhibitors

Publications (2)

Publication Number Publication Date
JP2022552834A JP2022552834A (ja) 2022-12-20
JP2022552834A5 true JP2022552834A5 (cg-RX-API-DMAC7.html) 2023-04-18

Family

ID=75438074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521147A Pending JP2022552834A (ja) 2019-10-10 2020-10-09 ミエロペルオキシダーゼ阻害剤のプロドラッグ

Country Status (11)

Country Link
US (1) US20240067651A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041735A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022552834A (cg-RX-API-DMAC7.html)
KR (1) KR20220080133A (cg-RX-API-DMAC7.html)
CN (1) CN114945573A (cg-RX-API-DMAC7.html)
AU (1) AU2020363903A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006381A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157260A1 (cg-RX-API-DMAC7.html)
IL (1) IL291891A (cg-RX-API-DMAC7.html)
MX (1) MX2022004203A (cg-RX-API-DMAC7.html)
WO (1) WO2021072140A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010902A (es) * 2020-03-05 2022-10-07 Biohaven Therapeutics Ltd Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa.
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012797A1 (en) * 1989-04-19 1990-11-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sulfer-containing xanthine derivatives as adenosin antagonists
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
WO2007069924A1 (en) * 2005-12-15 2007-06-21 Industrial Research Limited Deazapurine analogs of 4'-aza-l-nucleosides
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
SG11202000086PA (en) * 2017-07-17 2020-02-27 Astrazeneca Ab Mpo inhibitors for use in medicine

Similar Documents

Publication Publication Date Title
JP2022095872A5 (cg-RX-API-DMAC7.html)
JP2022542222A5 (cg-RX-API-DMAC7.html)
JP2019043957A5 (cg-RX-API-DMAC7.html)
CN109640953B (zh) 包含带有羧酸根电荷和疏水性基团的共聚氨基酸的可注射溶液
RU2006143664A (ru) Соединения для ингибирования ферментов
JP2022546609A5 (cg-RX-API-DMAC7.html)
JP2005514338A5 (cg-RX-API-DMAC7.html)
IL276322B1 (en) Lipid-like nanocomplexes and their uses
JP2012529433A5 (cg-RX-API-DMAC7.html)
CA2389681A1 (en) Npy y5 antagonist
PT1086124E (pt) Ciclosporinas novas
RU2014137107A (ru) Пептидомиметические макроциклы
JP2013511554A5 (cg-RX-API-DMAC7.html)
JP2008509166A5 (cg-RX-API-DMAC7.html)
CA2750413A1 (en) Hydroxamic acid derivatives
JP2016153410A5 (cg-RX-API-DMAC7.html)
JP2015110654A5 (cg-RX-API-DMAC7.html)
KR970042553A (ko) 캠프토테신 유도체
JP2005532287A5 (cg-RX-API-DMAC7.html)
JP2019509280A5 (cg-RX-API-DMAC7.html)
TWI811246B (zh) 胜肽化合物之製造方法
JP2002525284A5 (cg-RX-API-DMAC7.html)
RU2008126305A (ru) Новый пептид
KR20240171197A (ko) pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
RU2004127136A (ru) Способ получения гамма-амидов глутамовой кислоты